🔗 Share this article

The first new treatments for gonorrhoea in decades are being viewed as a "significant breakthrough" in the fight against increasingly resistant strains of the infection, according to scientists.

A Worldwide Public Health Issue

Gonorrhoea infections are escalating around the world, with figures suggesting more than 82 million infections annually. Particularly high rates are seen in Africa and countries within the World Health Organization's designated area, which spans from China and Mongolia to New Zealand. Across England, cases have reached a record high, while figures across Europe in 2023 were three times higher compared to figures for 2014.

“The authorization of new treatments for gonorrhoea is an critical and opportune advancement in the face of increasing worldwide cases, the spread of superbugs and the extremely scarce treatment choices currently available.”

Medical experts are deeply concerned about the rise in drug-resistant strains. The WHO has listed it as a "critical concern". Recent surveillance found that resistance to key first-line drugs like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Two New Therapies Secure Authorization

Zoliflodacin, also known as a brand name, was cleared by the US Food and Drug Administration in mid-December for combating gonorrhoea. This disease can lead to significant complications, including infertility. Scientists believe that targeted use of this new drug will help hinder the emergence of superbugs.

Gepotidacin, originating from the pharmaceutical company GlaxoSmithKline, gained clearance in the same week. This drug, which is employed against urinary tract infections, was shown in trials to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Partnership

This new treatment emerged from a unique collaborative effort for drug creation. The charitable organization GARDP partnered with the pharmaceutical company its industry partner to bring it to fruition.

“This milestone represents a major breakthrough in the therapy of multidrug-resistant gonorrhoea, which up to this point has been outpacing our drug pipeline.”

Research Study Data and Worldwide Availability

As per results published in a prominent scientific publication, the new drug cured more than 90% of cases of the STI. This establishes an similar efficacy with the typical regimen, which uses two antibiotics. The study enrolled nearly 1,000 volunteers from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its development partnership, GARDP has the rights to license and sell the drug in a wide range of regions with limited resources.

Clinicians directly involved have expressed hope. Having a easy-to-administer therapy of this kind is hailed as a "game-changer" for public health efforts. This is considered crucial to alleviate the strain of the infection for patients and to stop the proliferation of untreatable gonorrhoea globally.